Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Cosmos Health (COSM) EBITDA (2016 - 2025)

Cosmos Health's EBITDA history spans 13 years, with the latest figure at -$10.5 million for Q4 2025.

  • Quarterly results put EBITDA at -$10.5 million for Q4 2025, up 6.25% from a year ago — trailing twelve months through Dec 2025 was -$16.7 million (up 30.77% YoY), and the annual figure for FY2025 was -$16.7 million, up 30.77%.
  • EBITDA for Q4 2025 was -$10.5 million at Cosmos Health, down from -$5.1 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $213171.0 in Q1 2025 to a low of -$36.6 million in Q4 2022.
  • The 5-year median for EBITDA is -$3.6 million (2022), against an average of -$7.3 million.
  • The sharpest move saw EBITDA tumbled 11858.72% in 2021, then surged 108.64% in 2025.
  • Year by year, EBITDA stood at -$9.4 million in 2021, then crashed by 288.59% to -$36.6 million in 2022, then surged by 45.95% to -$19.8 million in 2023, then surged by 43.27% to -$11.2 million in 2024, then grew by 6.25% to -$10.5 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$10.5 million, -$5.1 million, and -$1.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.